Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chemotherapy + DC-activated CIK cells
- Development stage
- Unknown
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is a combination therapy that integrates standard chemotherapy with adoptive cell transfer of dendritic cell (DC)-activated cytokine-induced killer (CIK) cells. The approach aims to enhance anti-tumor immune responses by combining the cytotoxic effects of chemotherapy with the targeted immune activation provided by autologous DCs and CIK cells. Dendritic cells are antigen-presenting cells that process and present tumor antigens, while CIK cells are a heterogeneous population of T and NK-like lymphocytes expanded ex vivo using cytokines such as IL-2, IL-1, and IFN-γ. When combined, these therapies synergistically improve tumor recognition, cytotoxicity against cancer cells, and overall clinical outcomes in various solid tumors including colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC)[2][3][6].
- Other names
- Chemotherapy combined with dendritic cell-activated cytokine-induced killer cellsChemotherapy plus DC + CIK cells[2][3][4]
02
Targets
NCR3LG1 (Natural cytotoxicity triggering receptor 3 ligand 1)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on chemotherapy + DC-activated CIK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chemotherapy + DC-activated CIK cells.